Form 4: C4 Therapeutics CEO Andrew Hirsch Reports Stock Transactions
SEC Form 4 Filing
Andrew Hirsch, CEO of C4 Therapeutics, reports the vesting and tax withholding of performance restricted stock units.
Summary
- On September 16, 2024, Andrew Hirsch, the President & CEO of C4 Therapeutics, engaged in transactions involving the company's common stock.
- Hirsch acquired 7,500 shares of common stock through the vesting of performance restricted stock units (PRSUs).
- 3,329 shares were withheld by C4 Therapeutics to satisfy tax obligations related to the vesting of the PRSUs at a price of $6.36.
- Following these transactions, Hirsch directly owns 214,912 shares of C4 Therapeutics common stock and 47,500 performance restricted stock units.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects routine stock transactions related to executive compensation. The vesting of PRSUs suggests achievement of performance milestones, which is mildly positive.
Positives
- The vesting of PRSUs indicates the achievement of certain performance milestones, which can be viewed positively.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of stock transactions (PRSU vesting and tax withholding). |
| 09/17/2024 | Date of signature on the Form 4 filing. |
| 02/28/2025 | Expiration date of the Performance Restricted Stock Units |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.